Skip to main content

Voyageur Pharmaceuticals partners with Rain Cage to develop nanocarbon-based radiology drugs

--News Direct--

Voyageur Pharmaceuticals CEO Brent Willis join's Proactive's Natalie Stoberman to share a significant licensing agreement with Rain Cage Carbon to develop nanocarbon-based contrast drugs for medical imaging.

Willis says the partnership aims to develop new contrast agents for the radiology drug market while also making Voyageur the first carbon-neutral pharmaceutical company in the industry.

He explains that Rain Cage Carbon's innovative technology allows Voyageur to extract carbon dioxide and other emissions, generating high-grade carbon for various applications. By leveraging this technology, Willis says Voyageur plans to create safer and more effective drugs using carbon 60 molecules.

Contact Details

Proactive Investors

+1 604-688-8158

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.